LCTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LCTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
For the three months ended in Dec. 2023, Lineage Cell Therapeutics's Net Income From Continuing Operations was $-4.71 Mil. Its Depreciation, Depletion and Amortization was $0.18 Mil. Its Change In Working Capital was $-1.31 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $1.06 Mil. And its Cash Flow from Others was $-1.23 Mil. In all, Lineage Cell Therapeutics's Cash Flow from Operations for the three months ended in Dec. 2023 was $-6.02 Mil.
The historical data trend for Lineage Cell Therapeutics's Cash Flow from Operations can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lineage Cell Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cash Flow from Operations | Get a 7-Day Free Trial | -31.95 | -19.75 | -23.56 | 1.06 | -28.57 |
Lineage Cell Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cash Flow from Operations | Get a 7-Day Free Trial | -8.30 | -11.24 | -6.27 | -5.04 | -6.02 |
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
Lineage Cell Therapeutics's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Operations | (A: Dec. 2023 ) | ||||||
= | Net Income From Continuing Operations | + | Depreciation, Depletion and Amortization | + | Change In Working Capital | + | Deferred Tax |
= | -21.479 | + | 0.692 | + | -10.804 | + | -1.803 |
+ | Cash from Discontinued Operating Activities | + | Asset Impairment Charge | + | Stock Based Compensation | + | Cash Flow from Others |
+ | 0 | + | 0 | + | 4.64 | + | 0.188 |
= | -28.57 |
Lineage Cell Therapeutics's Cash Flow from Operations for the quarter that ended in Dec. 2023 is:
Cash Flow from Operations | (Q: Dec. 2023 ) | ||||||
= | Net Income From Continuing Operations | + | Depreciation, Depletion and Amortization | + | Change In Working Capital | + | Deferred Tax |
= | -4.714 | + | 0.175 | + | -1.313 | + | 0 |
+ | Cash from Discontinued Operating Activities | + | Asset Impairment Charge | + | Stock Based Compensation | + | Cash Flow from Others |
+ | 0 | + | 0 | + | 1.06 | + | -1.227 |
= | -6.02 |
Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lineage Cell Therapeutics (AMEX:LCTX) Cash Flow from Operations Explanation
For companies reported in indirect method, cash flow from operations contains six items:
1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.
Lineage Cell Therapeutics's net income from continuing operations for the three months ended in Dec. 2023 was $-4.71 Mil.
2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets
Lineage Cell Therapeutics's depreciation, depletion and amortization for the three months ended in Dec. 2023 was $0.18 Mil.
3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.
Lineage Cell Therapeutics's change in working capital for the three months ended in Dec. 2023 was $-1.31 Mil. It means Lineage Cell Therapeutics's working capital declined by $1.31 Mil from Sep. 2023 to Dec. 2023 .
4. Deferred Tax:
It is the cash flow generated from deferred tax.
Lineage Cell Therapeutics's cash flow from deferred tax for the three months ended in Dec. 2023 was $0.00 Mil.
5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.
Lineage Cell Therapeutics's cash from discontinued operating Activities for the three months ended in Dec. 2023 was $0.00 Mil.
6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.
Lineage Cell Therapeutics's asset impairment charge for the three months ended in Dec. 2023 was $0.00 Mil.
7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.
Lineage Cell Therapeutics's stock based compensation for the three months ended in Dec. 2023 was $1.06 Mil.
8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).
Lineage Cell Therapeutics's cash flow from others for the three months ended in Dec. 2023 was $-1.23 Mil.
Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.
Anula Jayasuriya | director | 5150 EL CAMINO REAL, SUITE #A-32, LOS ALTOS CA 94022 |
Jill Ann Howe | officer: Chief Financial Officer | C/O DTX PHARMA, INC., 10655 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121 |
Dipti Amin | director | C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008 |
Brian M Culley | director, officer: President and CEO | 6725 MESA RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121 |
Broadwood Partners Lp | 10 percent owner | BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019 |
Michael H. Mulroy | director | 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807 |
Gary S. Hogge | officer: SVP,Clinical & Medical Affairs | 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501 |
Samuel George A. Iii | officer: General Counsel/Secretary | C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008 |
Angus C. Russell | director | C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Kevin Leon Cook | officer: Chief Financial Officer | C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008 |
Alexandra Hernandez | officer: Sr Director Finance/Controller | C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008 |
Brandi Roberts | officer: CFO & SVP, Finance | 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130 |
Chase C. Leavitt | officer: General Counsel/Secretary | 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501 |
Edward Wirth | officer: Chief Medical Officer | C/O INVIVO THERAPEUTICS HOLDING CORP., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
Don M Bailey | director | 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92607 |
From GuruFocus
By PRNewswire PRNewswire • 07-14-2022
By PRNewswire PRNewswire • 10-15-2020
By PRNewswire PRNewswire • 06-24-2022
By gurujk gurujk • 06-27-2011
By PRNewswire PRNewswire • 07-04-2022
By PRNewswire PRNewswire • 04-20-2021
By Marketwired Marketwired • 01-07-2019
By PRNewswire PRNewswire • 01-30-2019
By PRNewswire PRNewswire • 06-14-2022
By Marketwired Marketwired • 01-30-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.